Abstract:Background Most patients with non-small-cell lung cancer tumours that have EGFR mutations have deletion mutations in exon 19 or the Leu858Arg point mutation in exon 21, or both (ie, common mutations). However, a subset of patients (10%) with mutations in EGFR have tumours that harbour uncommon mutations. There is a paucity of data regarding the sensitivity of these tumours to EGFR inhibitors. Here we present data for the activity of afatinib in patients with advanced non-small-cell lung cancer that have tumours harbouring uncommon EGFR mutations.Methods In this post-hoc analysis, we used prospectively collected data from tyrosine kinase inhibitor-naive patients with EGFR mutation-positive advanced (stage IIIb-IV) lung adenocarcinomas who were given afatinib in a single group phase 2 trial (LUX-Lung 2), and randomised phase 3 trials (LUX-Lung 3 and LUX-Lung 6). Analyses were done in the intention-to-treat population, including all randomly assigned patients with uncommon EGFR mutations. The type of EGFR mutation (exon 19 deletion [del19], Leu858Arg point mutation in exon 21, or other) and ethnic origin (LUX-Lung 3 only; Asian vs non-Asian) were pre-specified stratification factors in the randomised trials. We categorised all uncommon mutations as: point mutations or duplications in exons 18-21 (group 1); de-novo Thr790Met mutations in exon 20 alone or in combination with other mutations (group 2); or exon 20 insertions (group 3). We also assessed outcomes in patients with the most frequent uncommon mutations, Gly719Xaa, Leu861Gln, and Ser768Ile, alone or in combination with other mutations. Response was established by independent radiological review. These trials are registered with ClinicalTrials.gov, numbers NCT00525148, NCT00949650, and NCT01121393.Findings Of 600 patients given afatinib across the three trials, 75 (12%) patients had uncommon EGFR mutations (38 in group 1, 14 in group 2, 23 in group 3). 27 (71.1%, 95% CI 54.1-84.6) patients in group 1 had objective responses, as did two (14.3%, 1.8-42.8) in group 2 and two (8.7%, 1.1-28.0) in group 3. Median progression-free survival was 10.7 months (95% CI 5.6-14. 7) in group 1, 2.9 months (1.2-8.3) in group 2; and 2.7 months (1.8-4.2) in group 3. Median overall survival was 19.4 months (95% CI 16.4-26.9) in group 1, 14.9 months (8.1-24.9) in group 2, and 9.2 months (4.1-14.2) in group 3. For the most frequent uncommon mutations, 14 (77.8%, 95% CI 52.4-93.6) patients with Gly719Xaa had an objective response, as did nine (56.3%, 29.9-80.2) with Leu861Gln, and eight (100.0%, 63.1-100.0) with Ser768Ile.Interpretation Afatinib was active in non-small-cell lung cancer tumours that harboured certain types of uncommon EGFR mutations, especially Gly719Xaa, Leu861Gln, and Ser768Ile, but less active in other mutations types. Clinical benefit was lower in patients with de-novo Thr790Met and exon 20 insertion mutations. These data could help inform clinical decisions for patients with non-small-cell lung cancer harbouring uncommon EGFR mutations.

Efficacy and potential resistance mechanisms of afatinib in advanced non-small cell lung cancer patients with EGFR G719X/L861Q/S768I

Next-generation sequencing reveals genetic heterogeneity and resistance mechanisms in patients with EGFR-mutated non-small cell lung cancer treated with afatinib

Interim Analysis of Afatinib Monotherapy in Patients with Metastatic Nsclc Progressing after Chemotherapy and Erlotinib/Gefitinib (E/G) in A Trial of Afatinib Plus Paclitaxel Versus Investigator'S Choice Chemotherapy Following Progression on Afatinib Monotherapy

Afatinib As a Potential Therapeutic Option for Patients with NSCLC with EGFR G724S

Clinical Activity of Afatinib in Patients with Advanced Non-Small-Cell Lung Cancer Harbouring Uncommon Egfr Mutations: A Combined Post-Hoc Analysis of Lux-Lung 2, Lux-Lung 3, and Lux-Lung 6

Afatinib in the Treatment of Advanced NSCLC with EGFR Mutation: an Observational Real-World Study.

Comprehensive Analysis of EGFR-Mutant Abundance and Its Effect on Efficacy of EGFR TKIs in Advanced NSCLC with EGFR Mutations.

Durable response to afatinib in an advanced lung adenocarcinoma patient with an EGFR L858R/G729A compound mutation: a case report

Quantitative Test of Mutant Egfr and Its Effect on Efficacy of Egfr Tki in Advanced Nsclc

Afatinib, an effective treatment for patient with lung squamous cell carcinoma harboring uncommon EGFR G719A and R776C co-mutations

EGFR L858M/L861Q cis Mutations Confer Selective Sensitivity to Afatinib

Afatinib for the Treatment of Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: An Updated Database of 1023 Cases Brief Report

Successful Treatment of a Patient with NSCLC Carrying Uncommon Compound L861Q/G719X Epidermal Growth Factor Receptor Mutations Using Afatinib

Rare EGFR E709-T710delinsX: Molecular characteristics and superior response to afatinib treatment in NSCLC patients

Afatinib for the treatment of EGFR mutation-positive NSCLC: A review of clinical findings

Inconsistent clinical outcomes following afatinib treatment in NSCLC patients harboring uncommon epidermal growth factor receptor mutation

Efficacy and Safety of Afatinib in the Treatment of Advanced Non-Small-Cell Lung Cancer with EGFR Mutations: A Meta-Analysis of Real-World Evidence.

The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients

Co-occurring EGFR p.E709X mutation Mediates Primary Resistance to the Third-generation EGFR-TKIs in EGFR p.G719X-mutant Patients with Advanced NSCLC

Real-world Afatinib Outcomes in Advanced Non-small Cell Lung Cancer Harboring EGFR Mutations

Afatinib 30 Mg in the Treatment of Common and Uncommon EGFR-mutated Advanced Lung Adenocarcinomas: a Retrospective, Single-Center, Longitudinal Study